Hero CMP-16 Full spectrum vs broad spectrum vs isolate
Home/Compare/Full Spectrum vs Broad Spectrum vs Isolate

Full Spectrum vs Broad Spectrum vs Isolate: What Each One Contains

Full spectrum extract keeps every compound the plant made, including its THC. Broad spectrum is that extract with the THC taken out, and isolate is cannabidiol refined from everything else, usually 99 percent or higher.

No controlled trial has compared the three head to head, and the only cannabidiol with randomized controlled human data is highly purified.

Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic
Third Party TestedBatch Certificates Of AnalysisHighest QualityFull SpectrumGlobal Shipping100% Organic

At a glance

Property
Full spectrum
Broad spectrum
Isolate
What it is
Whole hemp extract: CBD, minor cannabinoids, terpenes, the plant's THC
Hemp extract run through a THC removal step; minor cannabinoids retained
One compound, crystalline CBD at 99% or higher
Where it comes from
Solvent or CO2 extraction, no cannabinoid removal stage
Full spectrum extract run through chromatography to strip THC
Chromatography then crystallization until only CBD remains
CB1 receptor
Only CB1 agonist present is THC; CBD does not activate CB1
No CB1 agonist once THC is removed
None; purified CBD does not activate CB1
CB2 receptor
THC is a CB2 agonist; CBD low efficacy at CB2
No cannabinoid receptor agonist of consequence remains
CBD alone, low efficacy at CB2
Most potent measured target
Not definable for a mixture; depends which cannabinoids the batch holds
Not definable; the term does not specify which compounds survive
CBD alone, which stimulated and desensitized human TRPV1 in a 2011 screen
Intoxicating
No at label doses, though THC is present and measurable
No
No
Human trials
No randomized controlled trial against purified CBD in any condition
No published controlled trial of a THC removed extract
Randomized placebo controlled trials of highly purified cannabidiol in Dravet and Lennox-Gastaut syndromes
Human pharmacokinetics
A 15 adult study of a 1:1 CBD to CBDa soft gel, measured to 48 hours
No published human pharmacokinetic study of a broad spectrum extract
From 24 human studies in a 2018 review; absolute oral bioavailability never established

What the three labels actually mean

None of these three words is a legal term. Each describes where a manufacturer stopped processing, and that is all it describes. Full spectrum means the extract was not put through a cannabinoid removal step, so it still carries minor cannabinoids, surviving terpenes and the THC the plant made, which in hemp is a small measurable fraction rather than an active ingredient.

Broad spectrum is the same extract after a separation stage, usually chromatography, that pulls out the THC fraction. Chromatography separates by chemical behavior rather than by name, so a step that removes THC removes compounds that behave like THC on that column, and no published study has measured what is left behind in a finished consumer extract. Two products both labeled broad spectrum can differ in which cannabinoids remain.

Isolate is the end of the same road: chromatography, then crystallization, until one compound is left and the certificate reports a single number. All three are usually made from decarboxylated material, so the acid forms CBDa and THCa have largely been converted by heat before the spectrum question arises at all.

Why the entourage argument is weaker than it sounds

CMP-16 Full spectrum vs broad spectrum vs isolate second section

The case for full spectrum rests on the entourage effect, and the strongest evidence cited is a 2018 meta-analysis of observational epilepsy data. It pooled 11 studies covering 670 patients: 71 percent on CBD rich extracts reported fewer seizures against 46 percent on purified CBD. That is the figure quoted in marketing.

The figure rarely quoted is in the same paper. At the standard clinical threshold, a 50 percent or greater reduction in seizure frequency, there was no difference between the two (p = 0.52). Patients on extracts also took a much lower average dose, 6.0 against 25.3 mg/kg a day, and the studies were observational rather than randomized. The authors said the synergy explanation remains to be confirmed in controlled studies.

A 2024 scoping review found limited evidence for the entourage effect as a stable and predictable phenomenon, and limited evidence for clinical efficacy or regulation built on it. Our reading: a reasonable hypothesis with weak human support. Which leaves an awkward fact for the usual pitch: the cannabidiol with randomized placebo controlled human data is a highly purified one.

What the research shows, and does not

Full spectrum
A 2018 meta-analysis of 11 observational studies in 670 refractory epilepsy patients recorded 71 percent reporting fewer seizures on CBD rich extracts against 46 percent on purified CBD.
At a 50 percent or greater seizure reduction, the same analysis found no difference between extracts and purified CBD (p = 0.52).
No randomized controlled trial has compared a full spectrum extract with purified CBD in any condition.
Broad spectrum
No controlled human trial of a THC removed broad spectrum extract has been published.
No published human pharmacokinetic study has measured plasma cannabinoids from a broad spectrum extract.
No legal definition exists, so two broad spectrum products can differ in which cannabinoids survive.
Isolate
Highly purified cannabidiol reduced convulsive seizure frequency against placebo in a randomized trial in Dravet syndrome (N Engl J Med 2017).
In the open label extension, 264 patients were treated a median 274 days at a mean modal dose of 21 mg/kg a day.
No trial has tested purified CBD outside those two rare epilepsy syndromes.

The pattern is uncomfortable for everyone. Full spectrum has observational data that weakens under scrutiny. Broad spectrum has no human data, being a processing category rather than a defined composition. Isolate has the trial evidence, in two rare syndromes at doses above consumer use.

What people get wrong

01Full spectrum is always stronger.
Strength is the measured CBD per milliliter on the certificate, not the number of compounds. A 15 percent full spectrum oil and a 15 percent isolate oil match.
02Broad spectrum gives you the entourage effect without the THC.
That assumes the step is selective for THC alone. Chromatography separates by chemical behavior, and no published study has measured what survives in a finished extract.
03Isolate has been stripped of everything that makes CBD work.
The only cannabidiol with randomized controlled human trial data is a highly purified preparation. Purity is not the weakness it is sold as being.
04The label tells you which of the three you bought.
Of 80 commercial CBD products analyzed by LC-MS/MS in 2022, 37 were more than 10 percent from their stated CBD content; agreement within 10 percent was 54 percent.

Choosing between them

Work backwards from the constraint that applies to you. If detectable THC is a problem, isolate is the only one of the three where refinement removes it rather than limiting it. If you want the extract closest to the plant and accept a small measurable THC content, full spectrum is that. Broad spectrum sits between, asking you to trust a step neither defined nor documented.

The entourage effect should not drive it, because the human evidence does not carry that weight. Read the certificate: the measured figures for CBD, CBDa, THC and THCa.

Still weighing up the options? See CBD isolate vs distillate, CBD vs THC or hemp oil vs CBD oil. For more background, read our guide on full-spectrum CBD oil. Endoca products related to this comparison: Full-spectrum CBD and CBD isolate.

How Endoca tests for this

Our hemp is grown on our own farm and extracted by us, as it has been since 2010. Every batch certificate reports CBD and CBDa separately alongside THC and THCa, so both the spectrum and the total THC that matters from 11 December 2026 are visible.

A certificate measures composition, not effect. RAW CBD+CBDa Oil 150mg is full spectrum and CBD Isolate 1000mg is the same hemp refined to 99 percent cannabidiol. We make no broad spectrum product, because we could not say what the removal step took with it.

Frequently asked questions

No. No randomized controlled trial has compared a full spectrum extract with purified CBD in any condition. The pooled analysis usually cited found a difference on self-reported improvement but none at the standard 50 percent seizure reduction threshold, and it was observational.

It is meant to contain none, but the term has no legal definition, so the only answer comes from the certificate of analysis. Look for THC and THCa reported below the laboratory’s limit of quantification rather than the words on the label.

It can. Full spectrum extracts contain THC by design, and workplace tests look for THC metabolites rather than CBD. If a test result matters, an isolate based product is the only one of the three where THC has been removed rather than limited.

Read the cannabinoid table on the certificate for that batch. Full spectrum shows THC and usually CBDa, a refined product CBD and little else. In a 2022 analysis of 80 CBD products, 37 were more than 10 percent off their stated CBD content.

It is the idea that cannabinoids and terpenes work better together than alone. It is plausible and often cited, but it has not been clearly demonstrated in human trials.

Full spectrum is a common starting point because it is closest to the plant. Anyone who is drug tested or wants to avoid THC entirely should choose broad spectrum or isolate.

References

01

Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 2017;376(21):2011-2020.

02

Devinsky O, Nabbout R, Miller I, et al. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial. Epilepsia 2019;60(2):294-302.

03

Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol 2018;9:759.

04

Simei JLQ, Souza JDR, Lisboa JR, et al. Does the Entourage Effect in Cannabinoids Exist? A Narrative Scoping Review. Cannabis Cannabinoid Res 2024;9(5):1202-1216.

05

Johnson E, Kilgore M, Babalonis S. Label accuracy of unregulated cannabidiol (CBD) products: measured concentration vs. label claim. J Cannabis Res 2022;4(1):28.

06

Millar SA, Stone NL, Yates AS, O’Sullivan SE. A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans. Front Pharmacol 2018;9:1365.

07

De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163(7):1479-1494.

08

Elder HJ, Zamarripa CA, Klausner M, et al. The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived Full-Spectrum Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid. Cannabis Cannabinoid Res 2025;10(2):e299-e313.

09

Lazarjani MP, Young O, Kebede L, Seyfoddin A. Processing and extraction methods of medicinal cannabis: a narrative review. J Cannabis Res 2021;3(1):32.

10

Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy. CRS In Focus IF13136, 28 September 2026.

Last reviewed 6 October 2026.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.